Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

6.81
-0.2250-3.20%
Volume:8K
Turnover:55.26K
Market Cap:12.85M
PE:-0.78
High:7.50
Open:7.04
Low:6.81
Close:7.03
52wk High:26.64
52wk Low:5.00
Shares:1.89M
Float Shares:1.29M
Volume Ratio:2.30
T/O Rate:0.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.7319
EPS(LYR):-8.7319
ROE:-2174.98%
ROA:-247.30%
PB:-8.24
PE(LYR):-0.78

Loading ...

NeuroSense announces departure of Chief Medical Officer

TIPRANKS
·
Apr 27

NeuroSense CMO Ferenc Tracik steps down, effective April 27

Reuters
·
Apr 24

NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042

Reuters
·
Apr 06

NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement

Reuters
·
Apr 03

Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM

TIPRANKS
·
Apr 02

NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership

Reuters
·
Apr 02

NeuroSense FY25 net loss widens 9% to USD 11.1 million

Reuters
·
Apr 01

NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement

Reuters
·
Apr 01

Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise

Reuters
·
Mar 31

BRIEF-NeuroSense Therapeutics FY EPS USD -0.44

Reuters
·
Mar 31

Neurosense Therapeutics FY Operating Income USD -11.085 Million

THOMSON REUTERS
·
Mar 31

Neurosense Therapeutics FY EPS USD -0.44

THOMSON REUTERS
·
Mar 31

Press Release: NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 31

NeuroSense files Form 3 for CTO Niva Russek-Blum initial beneficial ownership

Reuters
·
Mar 31

NeuroSense CEO Alon Ben-Noon files initial beneficial ownership statement

Reuters
·
Mar 30

NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks

Reuters
·
Mar 24

NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. Director Mark Leuchtenberger Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. files Form 3 initial beneficial ownership statement for General Manager Hagit Binder

Reuters
·
Mar 19